TrialCurveCONVERT: reconstructed Kaplan–Meier curves
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Lancet Oncol. 2017 Aug;18(8):1116–25. doi: 10.1016/S1470-2045(17)30318-2 |
|---|---|
| DOI | 10.1016/S1470-2045(17)30318-2 |
| Registry | NCT00433563 |
| Phase | NA |
| Conditions | Lung Cancer |
| Interventions | Once daily radiotherapy, Twice daily radiotherapy |
| Sponsor | The Christie NHS Foundation Trust |
| Enrolment | 547 |
| Source licence | Figure published under CC BY 4.0 |
Overall survival
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Twice-daily 29.5 months; Once-daily 25.0 months. Survival at 18 months: Twice-daily 67%; Once-daily 61%. Hazard ratio Twice-daily vs Once-daily 0.85 (95% CI 0.69–1.05).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Twice-daily | 273 | 164 | 29.5 |
| Once-daily | 270 | 175 | 25.0 |
- Twice-daily vs Once-daily: reconstructed HR 0.85 (95% CI 0.69–1.05)
Landmark survival (reconstructed)
| Time | Twice-daily | Once-daily |
|---|---|---|
| 6 mo | 94.5% | 93.3% |
| 12 mo | 83.0% | 76.4% |
| 18 mo | 66.7% | 61.2% |
| 24 mo | 56.3% | 51.0% |
| 36 mo | 43.0% | 39.2% |
| 48 mo | 37.9% | 33.0% |
| 60 mo | 34.9% | 30.7% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.18, reconstructed 1.17 pass
Local progression-free survival
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Twice-daily 21.4 months; Once-daily 18.7 months. Survival at 18 months: Twice-daily 54%; Once-daily 52%. Hazard ratio Twice-daily vs Once-daily 0.87 (95% CI 0.71–1.08).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Twice-daily | 273 | 168 | 21.4 |
| Once-daily | 270 | 181 | 18.7 |
- Twice-daily vs Once-daily: reconstructed HR 0.87 (95% CI 0.71–1.08)
Landmark survival (reconstructed)
| Time | Twice-daily | Once-daily |
|---|---|---|
| 6 mo | 92.9% | 93.6% |
| 12 mo | 76.8% | 68.3% |
| 18 mo | 54.2% | 51.6% |
| 24 mo | 46.4% | 42.3% |
| 36 mo | 38.3% | 35.7% |
| 48 mo | 34.3% | 31.0% |
| 60 mo | 32.2% | 27.5% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.15, reconstructed 1.15 pass
Metastatic progression-free survival
From figure panel C · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Twice-daily 19.9 months; Once-daily 16.3 months. Survival at 18 months: Twice-daily 53%; Once-daily 48%. Hazard ratio Twice-daily vs Once-daily 0.88 (95% CI 0.72–1.08).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Twice-daily | 273 | 174 | 19.9 |
| Once-daily | 270 | 181 | 16.3 |
- Twice-daily vs Once-daily: reconstructed HR 0.88 (95% CI 0.72–1.08)
Landmark survival (reconstructed)
| Time | Twice-daily | Once-daily |
|---|---|---|
| 6 mo | 90.5% | 91.4% |
| 12 mo | 69.0% | 60.2% |
| 18 mo | 53.0% | 48.1% |
| 24 mo | 45.1% | 42.8% |
| 36 mo | 39.0% | 36.4% |
| 48 mo | 35.7% | 32.0% |
| 60 mo | 32.2% | 29.4% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.13, reconstructed 1.14 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/convert-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/convert-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Lancet Oncol. 2017 Aug;18(8):1116–25. doi: 10.1016/S1470-2045(17)30318-2 doi:10.1016/S1470-2045(17)30318-2. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/convert
Report a problem with these data
Related trials
- ETER701: Overall survival; Progression-free survival (PFS)
- CA209-7AL: Progression-free survival
- LUNGSTAR: Overall survival; Progression-free survival
- KEYNOTE-671 (stage II subgroup): Event-free survival; Overall survival
- TOPICAL: Overall survival; Progression-free survival
- PIN: Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials